United Therapeutics Corp (UTHR) 96.20 $UTHR
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
United Therapeutics Shares Down 8.1% Since SmarTrend's Sell Call (UTHR)
Comtex SmarTrend(R) - Mon Apr 14, 11:22AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 8.15% as of today's recent price of $95.20.
United Therapeutics Rises 3.89% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 3.89% Rise
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Tue Apr 08, 6:59AM CDT
United Therapeutics (NASDAQ:UTHR) was upgraded from Hold to Buy at Standpoint Research today. The stock closed yesterday at $93.35 on volume of 1.4 million shares, above average daily volume of 821,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
United Therapeutics Has Returned 9.5% Since SmarTrend Recommendation (UTHR)
Comtex SmarTrend(R) - Mon Apr 07, 10:02AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 9.55% as of today's recent price of $93.75.
Shares of UTHR Down 11.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 31, 9:24AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 11.22% as of today's recent price of $92.01.
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
Today’s Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 26, 8:13AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Insmed , Exelixis , ...
Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin
PR Newswire - Wed Mar 26, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin® (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost(TM) by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with United Therapeutics.
Earnings Look Back: United Therapeutics Is Down 5.5% Since Reporting Quarterly Results 2 Weeks Ago (UTHR)
Comtex SmarTrend(R) - Mon Mar 17, 7:05AM CDT
Two weeks ago on February 25th, 2014 United Therapeutics (NASDAQ:UTHR) reported earnings and analysts, on average, expected earnings of $2.62 on sales of $297.8 million. The company actually reported EPS of $2.88 on sales of $289.0 million, beating EPS estimates by $0.26 and missing revenue estimates by $8.8 million. Shares of United Therapeutics have slipped from $100.50 to $94.96, representing a loss of 5.5%, since the company reported earnings 20 days ago.
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 4.97% Sell Off
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 4.97%
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Earnings Hindsight: Up 0.5% in Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Mar 10, 7:49AM CDT
When United Therapeutics (NASDAQ:UTHR) reported earnings 13 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $2.62 on sales of $297.8 million. The company actually reported EPS of $2.88 on sales of $289.0 million, beating EPS estimates by $0.26 and missing revenue estimates by $8.8 million. Shares of United Therapeutics have climbed from $100.50 to $100.96, representing a gain of 0.5% since the company reported earnings 13 days ago.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
InterMune Stuns Markets, but Is It Overvalued?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 28, 5:03PM CST
InterMune told investors during its fourth quarter conference call that results from its phase 3 Ascend trial studying Esbriet in idiopathic pulmonary fibrosis, or IPF, would likely be released early in the second quarter. Investors ended up...
United Therapeutics Slips on Q4 Earnings Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:10AM CST
The company's revenues lagged expectations.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
United Therapeutics Falls 3.86% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Feb 25, 6:08PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $99.16 to a high of $106.89. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $101.71 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
United Therapeutics Shares Down 8.1% Since SmarTrend's Sell Call (UTHR)
Comtex SmarTrend(R) - Mon Apr 14, 11:22AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 8.15% as of today's recent price of $95.20.
United Therapeutics Rises 3.89% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 3.89% Rise
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Tue Apr 08, 6:59AM CDT
United Therapeutics (NASDAQ:UTHR) was upgraded from Hold to Buy at Standpoint Research today. The stock closed yesterday at $93.35 on volume of 1.4 million shares, above average daily volume of 821,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
United Therapeutics Has Returned 9.5% Since SmarTrend Recommendation (UTHR)
Comtex SmarTrend(R) - Mon Apr 07, 10:02AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 9.55% as of today's recent price of $93.75.
Shares of UTHR Down 11.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 31, 9:24AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 11.22% as of today's recent price of $92.01.
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
Today’s Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 26, 8:13AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Insmed , Exelixis , ...
Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin
PR Newswire - Wed Mar 26, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin® (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost(TM) by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with United Therapeutics.
Earnings Look Back: United Therapeutics Is Down 5.5% Since Reporting Quarterly Results 2 Weeks Ago (UTHR)
Comtex SmarTrend(R) - Mon Mar 17, 7:05AM CDT
Two weeks ago on February 25th, 2014 United Therapeutics (NASDAQ:UTHR) reported earnings and analysts, on average, expected earnings of $2.62 on sales of $297.8 million. The company actually reported EPS of $2.88 on sales of $289.0 million, beating EPS estimates by $0.26 and missing revenue estimates by $8.8 million. Shares of United Therapeutics have slipped from $100.50 to $94.96, representing a loss of 5.5%, since the company reported earnings 20 days ago.
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 4.97% Sell Off
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 4.97%
Comtex SmarTrend(R) - Tue Mar 11, 5:53PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.00 to a high of $100.10. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $97.42 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Earnings Hindsight: Up 0.5% in Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Mar 10, 7:49AM CDT
When United Therapeutics (NASDAQ:UTHR) reported earnings 13 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $2.62 on sales of $297.8 million. The company actually reported EPS of $2.88 on sales of $289.0 million, beating EPS estimates by $0.26 and missing revenue estimates by $8.8 million. Shares of United Therapeutics have climbed from $100.50 to $100.96, representing a gain of 0.5% since the company reported earnings 13 days ago.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
InterMune Stuns Markets, but Is It Overvalued?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 28, 5:03PM CST
InterMune told investors during its fourth quarter conference call that results from its phase 3 Ascend trial studying Esbriet in idiopathic pulmonary fibrosis, or IPF, would likely be released early in the second quarter. Investors ended up...
United Therapeutics Slips on Q4 Earnings Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:10AM CST
The company's revenues lagged expectations.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
United Therapeutics Falls 3.86% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Feb 25, 6:08PM CST
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $99.16 to a high of $106.89. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $101.71 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
